MOMi Study Seeks to Increase Inclusion of Pregnant and Lactating Individuals in Research
A new team research effort seeks to shed light on how mothers pass immunity to their babies during pregnancy and lactation.
About Boris Juelg, MD, PhD
Dr. Juelg received an MD and PhD from Christian Albrecht University in Kiel, Germany. He completed a postdoctoral research fellowship with Dr. Bruce Walker before undergoing internal medicine training at MGH and a fellowship in infectious diseases through the combined program at MGH and Brigham and Women’s Hospital.
Clinical Interests:
- AIDS and HIV infection
- Infectious diseases
Treats:
- Adult
Languages:
- French, German
Locations
Mass General Infectious Diseases
55 Fruit St.
Boston, MA 02114
Phone: 617-726-3906
Medical Education
- PhD, Christian-Albrechts University
- Residency, Ludwig Maximilians University of Munich Medical School
- Residency, Massachusetts General Hospital
- Fellowship, Massachusetts General Hospital
American Board Certifications
- Infectious Disease, American Board of Internal Medicine
- Internal Medicine, American Board of Internal Medicine
Accepted Insurance Plans
- Aetna
- Beech Street
- Blue Cross Blue Shield
- Blue Cross Blue Shield Medicare
- Cigna
- Commonwealth Care Alliance
- Coventry
- Fallon Health
- Harvard Pilgrim Health Care
- Humana
- Maine Community Health Options
- Mass General Brigham Health Plan
- MassHealth
- Medicaid ME
- Medicaid NH
- Medicaid RI
- Medicaid VT
- Medicare
- Medicare ACO
- Multiplan
- Senior Whole Health
- TriCare
- Tufts Health Plan
- United Health Care
- Wellpoint
- WellSense
- WellSense NH
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
Research
Dr. Juelg aims to link preclinical and clinical studies to identify and test the most promising immunological strategies to prevent and treat viral infections such as HIV. He is specifically interested in evaluating passive and active immunization approaches using broadly neutralizing antibodies and novel vaccine candidates. Dr. Juelg is conducting phase I/II clinical trials that are testing such concepts and translating findings from the lab into the clinic.